Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Selinexor
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Karyopharm Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Prometrika and Karyopharm Partner in Global COVID-19 Trial
Details : Karyopharm and PROMETRIKA together will conduct the first randomized clinical trial for low-dose selinexor (XPOVIO®), an XPO1 inhibitor, in hospitalized patients with severe COVID-19.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
April 30, 2020
Lead Product(s) : Selinexor
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Karyopharm Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration